Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
Douglas G McNeelHamid EmamekhooJens C EickhoffChristos E KyriakopoulosEllen WargowskiTommaso P TonelliLaura E JohnsonGlenn LiuPublished in: Journal for immunotherapy of cancer (2023)
NCT03600350.